AGP Executive Report
Last update: 11 hours agoMedical Cannabis Marketing Scrutiny: Australia’s MOCA admitted it wrongly described its products as TGA-approved, even though most medicinal cannabis goods are not assessed by the regulator—raising fresh alarm about how clinics and online prescribers pitch CBD/THC care. Clinical CBD Progress: Avecho’s cannabidiol insomnia capsule trial moves into a second cohort after an independent board backed continuing enrolment, while Neurotech’s broad-spectrum cannabinoid autism study has dosed its first child in a pivotal “Beyond Harmony” push. Industry Pressure in Massachusetts: A new Q&A explains how Ballot Question 8 could repeal adult-use recreational marijuana sales in the state, despite record sales and a large business footprint. Regulation Updates: Missouri proposed rule changes for cannabis facility licensing and ownership, and Uganda’s government warned investors against diverting licensed medical cannabis and industrial hemp into illicit markets. Workplace Reality: A report notes more workers test positive for cannabis, even as some employers loosen screening—raising liability and workers’ comp concerns. Hemp THC Legal Fight (US): Congress moved to close a loophole that fueled the hemp-THC market, delaying the effective date and setting up a new regulatory fight.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
